Skip to main content
Top
Published in: BMC Infectious Diseases 1/2021

Open Access 01-12-2021 | Tuberculosis | Research article

Baseline Xpert MTB/RIF ct values predict sputum conversion during the intensive phase of anti-TB treatment in HIV infected patients in Kampala, Uganda: a retrospective study

Authors: Juliet Namugenyi, Joseph Musaazi, Achilles Katamba, Joan Kalyango, Emmanuel Sendaula, Andrew Kambugu, Jan Fehr, Barbara Castelnouvo, Yukari C. Manabe, Willy Ssengooba, Christine Sekaggya-Wiltshire

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

In resource-limited settings, sputum smear conversion is used to document treatment response. Many People living with HIV (PLHIV) are smear-negative at baseline. The Xpert MTB/RIF test can indirectly measure bacterial load through cycle threshold (ct) values. This study aimed to determine if baseline Xpert MTB/RIF could predict time to culture negativity in PLHIV with newly diagnosed TB.

Methods

A subset of 138 PLHIV from the ‘SOUTH’ study on outcomes related to TB and antiretroviral drug concentrations were included. Bacterial load was estimated by Mycobacterium Growth Indicator Tubes (MGIT) culture time-to-positivity (TTP) and Lowenstein Jensen (LJ) colony counts. Changes in TTP and colony counts were analyzed with Poisson Generalised Estimating Equations (GEE) and multilevel ordered logistic regression models, respectively, while time to culture negativity analysed with Cox proportional hazard models. ROC curves were used to explore the accuracy of the ct value in predicting culture negativity.

Results

A total of 81 patients (58.7%) were males, median age 34 (IQR 29  ̶ 40) years, median CD4 cell count of 180 (IQR 68  ̶ 345) cells/μL and 77.5% were ART naive. The median baseline ct value was 25.1 (IQR 21.0  ̶ 30.1). A unit Increase in the ct value was associated with a 5% (IRR = 1.05 95% CI 1.04  ̶ 1.06) and 3% (IRR = 1.03 95% CI 1.03  ̶ 1.04) increase in TTP at week 2 and 4 respectively. With LJ culture, a patient’s colony grade was reduced by 0.86 times (0R = 0.86 95% CI 0.74  ̶ 0.97) at week 2 and 0.84 times (OR = 0.84 95% CI 0.79  ̶ 0.95 P = 0.002) at week 4 for every unit increase in the baseline ct value. There was a 3% higher likelihood of earlier conversion to negativity for every unit increase in the ct value. A ct cut point ≥28 best predicted culture negativity at week 4 with a sensitivity of 91. 7% & specificity 53.7% while a cut point ≥23 best predicted culture negativity at week 8.

Conclusion

Baseline Xpert MTB/RIF ct values predict sputum conversion in PLHIV on anti-TB treatment. Surrogate biomarkers for sputum conversion in PLHIV are still a research priority.
Literature
1.
go back to reference WHO. Global Tuberculosis Report; 2020. p. 2020. WHO. Global Tuberculosis Report; 2020. p. 2020.
3.
go back to reference Hesseling A, Walzl G, Enarson D, Carroll N, Duncan K, Lukey P, et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberculosis Lung Dis. 2010;14(5):560–70. Hesseling A, Walzl G, Enarson D, Carroll N, Duncan K, Lukey P, et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberculosis Lung Dis. 2010;14(5):560–70.
4.
go back to reference Parikh R, Nataraj G, Kanade S, Khatri V, Mehta P. Time to sputum conversion in smear positive pulmonary TB patients on category I DOTS and factors delaying it. J Assoc Physicians India. 2012;60(22):6. Parikh R, Nataraj G, Kanade S, Khatri V, Mehta P. Time to sputum conversion in smear positive pulmonary TB patients on category I DOTS and factors delaying it. J Assoc Physicians India. 2012;60(22):6.
9.
go back to reference World Health Organization. Tuberculosis diagnostics: Xpert MTB/RIF test. Updated WHO recommendations as of October; 2013. p. 2013. World Health Organization. Tuberculosis diagnostics: Xpert MTB/RIF test. Updated WHO recommendations as of October; 2013. p. 2013.
11.
15.
go back to reference Agbor AA, Bigna JJR, Billong SC, Tejiokem MC, Ekali GL, Plottel CS, et al. Factors associated with death during tuberculosis treatment of patients co-infected with HIV at the Yaoundé Central Hospital, Cameroon: an 8-year hospital-based retrospective cohort study (2006–2013). PLoS one. 2014;9(12):e115211. https://doi.org/10.1371/journal.pone.0115211. Agbor AA, Bigna JJR, Billong SC, Tejiokem MC, Ekali GL, Plottel CS, et al. Factors associated with death during tuberculosis treatment of patients co-infected with HIV at the Yaoundé Central Hospital, Cameroon: an 8-year hospital-based retrospective cohort study (2006–2013). PLoS one. 2014;9(12):e115211. https://​doi.​org/​10.​1371/​journal.​pone.​0115211.   
17.
go back to reference Jeena P, Pillay P, Pillay T, Coovadia H. Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. Int J Tuberculosis Lung Dis. 2002;6(8):672–8. Jeena P, Pillay P, Pillay T, Coovadia H. Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. Int J Tuberculosis Lung Dis. 2002;6(8):672–8.
18.
go back to reference Kang’Ombe C, Harries AD, Ito K, Clark T, Nyirenda T, Aldis W, et al. Long-term outcome in patients registered with tuberculosis in Zomba, Malawi: mortality at 7 years according to initial HIV status and type of TB. Int J Tuberculosis Lung Dis. 2004;8(7):829–36. Kang’Ombe C, Harries AD, Ito K, Clark T, Nyirenda T, Aldis W, et al. Long-term outcome in patients registered with tuberculosis in Zomba, Malawi: mortality at 7 years according to initial HIV status and type of TB. Int J Tuberculosis Lung Dis. 2004;8(7):829–36.
19.
20.
go back to reference Nolte F, Metchock B. Mycobacterium, p 400–437. Manual of clinical microbiology, 6th ed. Washington, DC: ASM Press; 1995. Nolte F, Metchock B. Mycobacterium, p 400–437. Manual of clinical microbiology, 6th ed. Washington, DC: ASM Press; 1995.
21.
go back to reference StataCorp L. Stata statistical software: Release 13. College Station, TX: StataCorp LP; 2013. StataCorp L. Stata statistical software: Release 13. College Station, TX: StataCorp LP; 2013.
27.
go back to reference Murthy S, Chatterjee F, Crook A, Dawson R, Mendel C, Murphy M, et al. Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis. BMC Med. 2018;16(1):1–11.CrossRef Murthy S, Chatterjee F, Crook A, Dawson R, Mendel C, Murphy M, et al. Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis. BMC Med. 2018;16(1):1–11.CrossRef
Metadata
Title
Baseline Xpert MTB/RIF ct values predict sputum conversion during the intensive phase of anti-TB treatment in HIV infected patients in Kampala, Uganda: a retrospective study
Authors
Juliet Namugenyi
Joseph Musaazi
Achilles Katamba
Joan Kalyango
Emmanuel Sendaula
Andrew Kambugu
Jan Fehr
Barbara Castelnouvo
Yukari C. Manabe
Willy Ssengooba
Christine Sekaggya-Wiltshire
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-06220-6

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.